LinkedIn-button

Services

Vaccine
development
service

The bridge between discovery
and pilot-scale GMP biomanufacturing.
Intravacc offers a one-stop shop
for independent vaccine development,
from discovery to pilot production
to clinical studies.

LEARN MORE
LinkedIn-button

Discover
Intravacc

Intravacc, located at Utrecht Science Park Bilthoven in the Netherlands, is a leading global contract development and manufacturing organization of innovative vaccines against infectious diseases. With over 100 years of experience in vaccine development and optimization, Intravacc has transferred its technology related to polio vaccines, measles vaccines, DPT vaccines, Hib vaccines and influenza vaccines around the world.

LEARN MOREANNUAL REPORT 2021
LinkedIn-button

Latest News

Intravacc’s CSO Virgil Schijns appointed as Visiting Professor at the Scottish University of Strathclyde in Glasgow

Intravacc’s CSO Virgil Schijns appointed as Visiting Professor at the Scottish University of Strathclyde in Glasgow Appointment for three years at the Strathclyde Institute of Pharmacy and Biomedical Sciences Schijns published over 120 scientific papers in the field of immunology…

The University of Strathclyde in Glasgow is recognized as a leading international technological university. The appointment of Prof. Schijns will be in the context to further strengthen the pharmacy & biomedical sciences education and research capabilities. During his three years assignment as Visiting Professor Schijns, will teach several courses. He will partake in research discussions and speak during lectures on the relevant areas, as well as participate in series of engagements with students, and academic colleagues.
Read more

Intravacc Announces Favorable Preclinical Data for its Candidate Intranasal Gonorrhea Vaccine Avacc 11®

• Pre-clinical data of Avacc 11® demonstrated protection against gonorrhea infection • Global incidence rate of this sexual transmitted disease is at 87 million infections per year • OMV technology is a powerful tool to induce protective systemic and mucosal…

• Pre-clinical data of Avacc 11® demonstrated protection against gonorrhea infection • Global incidence rate of this sexual transmitted disease is at 87 million infections per year • OMV technology is a powerful tool to induce protective systemic and mucosal immunity • Data published in the peer reviewed journal MSphere of the American Society of Microbiology
Read more
LinkedIn-button

Career

Join our team!

Are you interested in becoming part of an innovative community, to learn alongside top scientists, to work with state-of-the art equipment, to get an inside look of and contribute to the biotech sector, where industry leaders, government, universities and international non-governmental organizations collaborate? Then Intravacc is the place for you.

YOUR CAREER?

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.